We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.39 | -0.43% | 91.23 | 91.00 | 91.62 | 91.72 | 89.63 | 91.38 | 1,682,358 | 16:40:00 |
From Apr 2019 to Apr 2024
By Michael Dabaie
Voyager Therapeutics Inc. (VYGR) shares were up 9% to $26.52 in midday trading Monday.
The clinical-stage gene therapy company said earlier it restructured its gene therapy relationship with Sanofi Genzyme.
Voyager said it is gaining world-wide rights to the VY-HTT01 Huntington's disease program and ex-U.S. rights to the VY-FXN01 Friedreich's ataxia program. Voyager is, in turn, transferring the ex-U.S. rights to VY-FXN01 to Neurocrine Biosciences Inc. (NBIX) under the terms of a collaboration agreement.
Neurocrine shares were up 2.3% to $85.82.
To focus resources on the now wholly-owned Huntington's disease program, Voyager said it would seek a partner to advance its preclinical program for SOD1 amyotrophic lateral sclerosis. Voyager said it no longer expects to file an investigational new drug application with the U.S. Food and Drug Administration for its VY-SOD102 in 2019.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 17, 2019 13:02 ET (17:02 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
